Analysis of KDELC1 and PTTG2 cfRNA abundance in 20 serum samples from metastatic patients with transcriptome‐defined tumor subtype from the COMPASS trial showed that the AUC for KDELC1 and PTTG2 was 0.64 and 0.69, respectively (Fig. 4F). Here, POGLUT2 is linked to neoplasm.